Affymetrix Disagrees with Incyte, Hyseq on Patent Ruling | GenomeWeb

NEW YORK, Jan 26 – Just hours after Incyte and Hyseq proclaimed that a ruling in their patent infringement cases with Affymetrix favored them, Affymetrix issued a conflicting statement, saying the ruling actually protects its patent position.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.